OTCQB
PPCB

Propanc Biopharma Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Propanc Biopharma Inc Stock Price

Vitals

Today's Low:
$0.03
Today's High:
$0.039
Open Price:
$0.036
52W Low:
$0.0001
52W High:
$0.2
Prev. Close:
$0.03
Volume:
346270

Company Statistics

Market Cap.:
$98652
Book Value:
-1.122
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-864.55%
Return on Equity TTM:
0%

Company Profile

Propanc Biopharma Inc had its IPO on under the ticker symbol PPCB.

The company operates in the Healthcare sector and Biotechnology industry. Propanc Biopharma Inc has a staff strength of 1 employees.

Stock update

Shares of Propanc Biopharma Inc opened at $0.04 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.03 - $0.04, and closed at $0.03.

This is a 0% increase from the previous day's closing price.

A total volume of 346,270 shares were traded at the close of the day’s session.

In the last one week, shares of Propanc Biopharma Inc have slipped by -30.23%.

Propanc Biopharma Inc's Key Ratios

Propanc Biopharma Inc has a market cap of $98652, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months Propanc Biopharma Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-2164400. The EBITDA ratio measures Propanc Biopharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Propanc Biopharma Inc’s operating margin was 0% while its return on assets stood at -864.55% with a return of equity of 0%.

In Q1, Propanc Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Propanc Biopharma Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-1.85 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Propanc Biopharma Inc’s profitability.

Propanc Biopharma Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.6952. Its price to sales ratio in the trailing 12-months stood at 0.

Propanc Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$143742.00
Total Liabilities
$3.06 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Propanc Biopharma Inc ended 2024 with $143742.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $143742.00 while shareholder equity stood at $-2941414.00.

Propanc Biopharma Inc ended 2024 with $0 in deferred long-term liabilities, $3.06 million in other current liabilities, 2621298.00 in common stock, $-63878972.00 in retained earnings and $0 in goodwill. Its cash balance stood at $93241.00 and cash and short-term investments were $93241.00. The company’s total short-term debt was $717,499 while long-term debt stood at $0.

Propanc Biopharma Inc’s total current assets stands at $96575.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $3334.00 compared to accounts payable of $2.24 million and inventory worth $0.

In 2024, Propanc Biopharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Propanc Biopharma Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.03
52-Week High
$0.2
52-Week Low
$0.0001
Analyst Target Price
$

Propanc Biopharma Inc stock is currently trading at $0.03 per share. It touched a 52-week high of $0.2 and a 52-week low of $0.2. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.07 and 200-day moving average was $0.03 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 45.5% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Propanc Biopharma Inc

The stock symbol (also called stock or share ticker) of Propanc Biopharma Inc is PPCB

The IPO of Propanc Biopharma Inc took place on

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
PB Fintech Limited (POLICYBZR)
$784.45
-10.9
-1.37%
$11.55
-0.48
-3.99%
$14.07
-0.26
-1.81%
$2889.5
-154
-5.06%
$2437.95
-36.45
-1.47%
$0.01
0
0%
Ashford Inc (AINC)
$8.19
0.01
+0.12%
$261.5
-9.85
-3.63%
$4.04
0.01
+0.25%
$155.25
-9.25
-5.62%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Address

302, 6 Butler Street, Camberwell, VIC, Australia, 3124